2.50
Hdl Handle:
http://hdl.handle.net/2336/13072
Title:
Improved outcome after relapse in children with acute myeloid leukaemia
Authors:
Abrahamsson, Jonas; Clausen, Niels; Gustafsson, Göran; Hovi, Liisa; Jonmundsson, Gudmundur; Zeller, Bernward; Forestier, Erik; Heldrup, Jesper; Hasle, Henrik
Citation:
Br. J. Haematol. 2007, 136(2):229-236
Issue Date:
1-Jan-2007
Abstract:
In the Nordic Society for Paediatric Haematology and Oncology paediatric study acute myeloid leukaemia (AML) 93, event-free survival was 50% and overall survival was 66%, indicating that many patients were cured following relapse. Factors influencing outcome in children with relapsed AML were investigated. The study included all 146 children in the Nordic countries diagnosed with AML between 1988 and 2003, who relapsed. Data on disease characteristics and relapse treatment were related to outcome. Sixty-six percentage achieved remission with survival after relapse (5 years) 34 +/- 4%. Of 122 patients who received re-induction therapy, 77% entered remission with 40 +/- 5% survival. Remission rates were similar for different re-induction regimens but fludarabine, cytarabine, granulocyte colony-stimulating factor-based therapy had low treatment-related mortality. Prognostic factors for survival were duration of first complete remission (CR1) and stem cell transplantation (SCT) in CR1. In early relapse (<1 year in CR1), survival was 21 +/- 5% compared with 48 +/- 6% in late relapse. For children receiving re-induction therapy, survival in early relapse was 29 +/- 6% and 51 +/- 6% in late. Patients treated in CR1 with SCT, autologous SCT or chemotherapy had a survival of 18 +/- 9, 5 +/- 5 and 41 +/- 5%, respectively. Survival was 62 +/- 6% in 64 children given SCT as part of their relapse therapy. A significant proportion of children with relapsed AML can be cured, even those with early relapse. Children who receive re-induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.2006.06419.x

Full metadata record

DC FieldValue Language
dc.contributor.authorAbrahamsson, Jonas-
dc.contributor.authorClausen, Niels-
dc.contributor.authorGustafsson, Göran-
dc.contributor.authorHovi, Liisa-
dc.contributor.authorJonmundsson, Gudmundur-
dc.contributor.authorZeller, Bernward-
dc.contributor.authorForestier, Erik-
dc.contributor.authorHeldrup, Jesper-
dc.contributor.authorHasle, Henrik-
dc.date.accessioned2007-08-02T14:39:38Z-
dc.date.available2007-08-02T14:39:38Z-
dc.date.issued2007-01-01-
dc.date.submitted2007-07-02-
dc.identifier.citationBr. J. Haematol. 2007, 136(2):229-236en
dc.identifier.issn0007-1048-
dc.identifier.pmid17278259-
dc.identifier.doi10.1111/j.1365-2141.2006.06419.x-
dc.identifier.otherPED12en
dc.identifier.urihttp://hdl.handle.net/2336/13072-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractIn the Nordic Society for Paediatric Haematology and Oncology paediatric study acute myeloid leukaemia (AML) 93, event-free survival was 50% and overall survival was 66%, indicating that many patients were cured following relapse. Factors influencing outcome in children with relapsed AML were investigated. The study included all 146 children in the Nordic countries diagnosed with AML between 1988 and 2003, who relapsed. Data on disease characteristics and relapse treatment were related to outcome. Sixty-six percentage achieved remission with survival after relapse (5 years) 34 +/- 4%. Of 122 patients who received re-induction therapy, 77% entered remission with 40 +/- 5% survival. Remission rates were similar for different re-induction regimens but fludarabine, cytarabine, granulocyte colony-stimulating factor-based therapy had low treatment-related mortality. Prognostic factors for survival were duration of first complete remission (CR1) and stem cell transplantation (SCT) in CR1. In early relapse (<1 year in CR1), survival was 21 +/- 5% compared with 48 +/- 6% in late relapse. For children receiving re-induction therapy, survival in early relapse was 29 +/- 6% and 51 +/- 6% in late. Patients treated in CR1 with SCT, autologous SCT or chemotherapy had a survival of 18 +/- 9, 5 +/- 5 and 41 +/- 5%, respectively. Survival was 62 +/- 6% in 64 children given SCT as part of their relapse therapy. A significant proportion of children with relapsed AML can be cured, even those with early relapse. Children who receive re-induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%.en
dc.language.isoenen
dc.publisherBlackwell Scientific Publicationsen
dc.relation.urlhttp://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.2006.06419.xen
dc.subject.meshAcute Diseaseen
dc.subject.meshAdolescenten
dc.subject.meshAntineoplastic Combined Chemotherapy Protocolsen
dc.subject.meshCytarabineen
dc.subject.meshCytogeneticsen
dc.subject.meshDisease-Free Survivalen
dc.subject.meshGranulocyte Colony-Stimulating Factoren
dc.subject.meshLeukemia, Myeloiden
dc.subject.meshVidarabineen
dc.subject.meshStem Cell Transplantationen
dc.titleImproved outcome after relapse in children with acute myeloid leukaemiaen
dc.typeArticleen
dc.format.digYES-

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.